{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:18:53Z","timestamp":1768537133361,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","award":["MOHW109-CDC-C-315-114403"],"award-info":[{"award-number":["MOHW109-CDC-C-315-114403"]}],"id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","award":["MOHW110-CDC-C-315-114405"],"award-info":[{"award-number":["MOHW110-CDC-C-315-114405"]}],"id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jmii.2023.08.013","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T19:15:40Z","timestamp":1693854940000},"page":"1236-1244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan"],"prefix":"10.1016","volume":"56","author":[{"given":"Hsin-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Hua","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwen","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jmii.2023.08.013_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.jmii.2023.08.013_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jmii.2023.08.013_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/JCM.01454-06","volume":"45","author":"Somoskovi","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.jmii.2023.08.013_bib8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JCM.05286-11","article-title":"High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility","volume":"50","author":"Devasia","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jmii.2023.08.013_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmii.2022.08.004","article-title":"Surveillance of multidrug-resistant tuberculosis in Taiwan, 2008-2019","volume":"56","author":"Wu","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"10.1016\/j.jmii.2023.08.013_bib11","first-page":"640","article-title":"Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis","volume":"9","author":"Laserson","year":"2005","journal-title":"Int J Tubercul Lung Dis"},{"issue":"4","key":"10.1016\/j.jmii.2023.08.013_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/jcm.35.4.907-914.1997","article-title":"Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology","volume":"35","author":"Kamerbeek","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"10","key":"10.1016\/j.jmii.2023.08.013_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2023.08.013_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095645","article-title":"Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California","volume":"9","author":"Budzik","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jmii.2023.08.013_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02170-16","article-title":"Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2023.08.013_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.tube.2017.12.007","article-title":"Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia","volume":"109","author":"Bwalya","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2023.08.013_bib17","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijmyco.2016.10.015","article-title":"The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide","volume":"5","author":"Daneau","year":"2016","journal-title":"Int J Mycobacteriol"},{"issue":"2","key":"10.1016\/j.jmii.2023.08.013_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5588\/ijtld.19.0314","article-title":"Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility","volume":"24","author":"Park","year":"2020","journal-title":"Int J Tubercul Lung Dis"},{"issue":"10","key":"10.1016\/j.jmii.2023.08.013_bib20","first-page":"e86","article-title":"Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates","volume":"6","author":"Huy","year":"2017","journal-title":"Emerg Microb Infect"},{"issue":"1","key":"10.1016\/j.jmii.2023.08.013_bib21","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1038\/s41598-019-45566-5","article-title":"Mycobacterium tuberculosis whole genome sequencing provides insights into the Manila strain and drug-resistance mutations in the Philippines","volume":"9","author":"Phelan","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jmii.2023.08.013_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.5588\/ijtld.18.0710","article-title":"Indo-Oceanic Mycobacterium tuberculosis strains from Thailand associated with higher mortality","volume":"23","author":"Smittipat","year":"2019","journal-title":"Int J Tubercul Lung Dis"},{"issue":"2","key":"10.1016\/j.jmii.2023.08.013_bib23","doi-asserted-by":"crossref","first-page":"e4540","DOI":"10.1371\/journal.pone.0004540","article-title":"In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi--predominance of drug resistant isolates of the 'modern' (TbD1) type","volume":"4","author":"Stavrum","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jmii.2023.08.013_bib24","doi-asserted-by":"crossref","first-page":"e814","DOI":"10.1111\/tbed.14371","article-title":"Bovine tuberculosis in Taiwan, 2008-2019","volume":"69","author":"Chan","year":"2022","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.jmii.2023.08.013_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2014.03.1388","article-title":"Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates","volume":"26","author":"Ho","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2023.08.013_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3904\/kjim.2018.052","article-title":"Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study","volume":"34","author":"Kim","year":"2019","journal-title":"Korean J Intern Med (Engl Ed)"},{"issue":"5","key":"10.1016\/j.jmii.2023.08.013_bib27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5588\/ijtld.17.0483","article-title":"Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan","volume":"22","author":"Kuhlin","year":"2018","journal-title":"Int J Tubercul Lung Dis"},{"issue":"1","key":"10.1016\/j.jmii.2023.08.013_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12879-019-3757-1","article-title":"Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania","volume":"19","author":"Juma","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.jmii.2023.08.013_bib29","doi-asserted-by":"crossref","first-page":"e3511","DOI":"10.1093\/cid\/ciaa1509","article-title":"Genotypic resistance of pyrazinamide but not minimum inhibitory concentration is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis","volume":"73","author":"Kuhlin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2023.08.013_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01770-2018","article-title":"Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study","volume":"53","author":"Sun","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jmii.2023.08.013_bib31","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1128\/JCM.02532-16","article-title":"Non-pncA gene-mutated but pyrazinamide-resistant Mycobacterium tuberculosis: why is that?","volume":"55","author":"Werngren","year":"2017","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223001640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118223001640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:30:06Z","timestamp":1761658206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118223001640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1684118223001640"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2023.08.013","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2023.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}